Follow-up of Long-term Treatment with Clean Intermittent Catheterization for Neurogenic Bladder in Children  by Lertsithichai, Panuwat et al.
134 ASIAN JOURNAL OF SURGERY  VOL 27 • NO 2 • APRIL 2004
070/2001
Original Article
© 2004 Elsevier. All rights reserved.
Introduction
More than 90% of paediatric neurogenic bladders in our hos-
pital are due to myelomeningocele. Although in some develop-
ing countries, the incidence of myelomeningocele at birth is
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declining due to prenatal investigations, thus obviating the
need to treat neonates with a major abnormality, this is not yet
the case in Thailand. Neurogenic bladder is a serious compli-
cation resulting in renal deterioration from vesicoureteral
reflux, hydronephrosis and infection.
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OBJECTIVES: To assess the results of long-term clean intermittent catheterization (CIC) treatment for
neurogenic bladder in children born with myelomeningocele, and to compare the long-term results between the
early treatment group (< 1 year old) and late treatment group (> 3 years old).
METHODS: Thirty-six paediatric patients with myelomeningocele who were treated in the first year of life
(Group 1) and 31 cases who were treated after the age of 3 years (Group 2) were followed regularly for at least 11
years. All medical records were reviewed and long-term results of treatment, including increases in blood urea
nitrogen (BUN) and serum creatinine, development of hydronephrosis, recurrent upper urinary tract infection,
and the number of augmentation cystoplasties needed, were noted. Kaplan-Meier methods were used to analyse
time-to-event data.
RESULTS: Mean age at start of treatment was 6.88 months (range, 3–11 months) in Group 1 and 44.97 months
(range, 37–60 months) in Group 2. Increases in BUN and serum creatinine were found in 12 cases (33.3%) in Group
1 and 19 cases (61.3%) in Group 2. Patients in Group 2 showed earlier renal deterioration and worse renal function
at the last follow-up. Hydronephrosis was found in 10 cases (27.8%) in Group 1 and 18 cases (58.1%) in Group 2.
Patients in Group 2 also had earlier and more severe hydronephrosis. Augmentation cystoplasty was needed in five
cases (13.9%) in Group 1 and 10 cases (32.3%) in Group 2 .The results of surgery were better in Group 1 than in
Group 2, and surgery was needed earlier in Group 2 compared with Group 1. There was no significant difference
regarding upper urinary tract infection between the two groups.
CONCLUSIONS: For most patients and with close long-term follow-up, early treatment of neurogenic bladder
using CIC in children born with myelomeningocele yields better results than late treatment. In our experience,
treatment is recommended as soon as possible, especially during the first year of life. [Asian J Surg 2004;27(2):
134–6]
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Before 1971, the definitive treatment for paediatric neuro-
genic bladder was catheterization and urinary diversion, but
since 1971, clean intermittent catheterization (CIC) has been
more widely used.1 CIC was suggested by Lapides et al2 and
Klose et al.3 Routine use of CIC has meant that these children
are no longer pariahs among their peers and in society.
Since 1981, we have used CIC to treat all patients, even
those with low bladder compliance, high filling pressure and
a leak point pressure of more than 40 cmH2O. We compared
the long-term results between early treatment (< 1 year old)
and late treatment (> 3 years old).
Patients and methods
A retrospective chart review was performed for all patients
who underwent primary neurosurgical repair of myelomen-
ingocele. Of the 67 patients, 36 (Group 1) were treated with
CIC before 1 year of age and 31 (Group 2) were treated after 3
years of age. Patients in Group 2 were referred to our unit for
further treatment from other hospitals and, thus, the reasons
for delayed treatment were not known. Pretreatment evalua-
tion of the severity of neurogenic bladder was not performed
routinely, as this was neither economically feasible nor avail-
able in all cases. Anticholinergic medication was used in either
group if abnormal detrusor contraction was demonstrated.
Augmentation cystoplasty with or without ureteroneocysto-
stomy was performed in patients with high-grade vesicoureter-
al reflux and poor bladder compliance or in whom medical
treatment had failed. We compared rates of urinary infection,
hydronephrosis and impaired renal function between the
groups. A blood urea nitrogen (BUN) of more than 10 mg%
was considered increased BUN, and a serum creatinine great-
er than 1.0 mg% was considered increased serum creatinine.
Continuous variables were tested using the t test or
Wilcoxon rank sum test, as appropriate, and categorical vari-
ables were tested using the Chi-squared test. Time-to-event
variables were analysed using Kaplan-Meier methods and com-
pared using the log-rank test.
Results
The age of Group 1 patients ranged from 3 to 11 months
(mean ± standard deviation, SD, 6.88 ± 2.36 months), and that
of Group 2 patients ranged from 37 to 60 months (mean ± SD,
44.96 ± 6.45 months). The median follow-up time for Group 1
patients was 202 months (range, 173–243 months), and that
for Group 2 patients was 165 months (range, 132–201 months).
There was no statistically significant difference in the age at
last follow-up between the two groups, meaning that patients
in Group 1 were followed for a longer time than those in Group
2. Increased BUN and creatinine were found in 12 cases
(33.3%) in Group 1 and 19 cases (61.3%) in Group 2 (p = 0.022)
(Table). Kaplan-Meier curves for time to increased BUN and
creatinine are shown in Figure 1. BUN and serum creatinine
increased earlier in Group 2 than in Group 1 (log-rank test,
p = 0.078). Ten cases in Group 1 (27.8%) and 18 cases in Group
2 (58.1%) had upper tract dilatation (p = 0.012). Group 2
patients showed earlier and more severe dilatation of the upper
tracts than those in Group 1 (log-rank test, p = 0.028) (Figure
2). Ten patients in Group 2 (32.3%) required complex surgical
procedures to correct complications at an earlier period than
five patients (13.9%) in Group 1 (log-rank, p = 0.132) (Figure 3).
Upper tract infection was found in nine cases (25.0%) in Group
1 and 14 cases (45.2%) in Group 2, but this was not a statisti-
cally significant difference. Although the difference in the
proportions of patients with increased BUN and serum creati-
nine in each group was statistically significant, the significance
became marginal when the timing of events was also taken into
account (i.e. time-to-event Kaplan-Meier analysis).
Discussion
CIC is an accepted form of therapy for urinary incontinence
and preservation of renal function in children with myelo-
meningocele,3 in whom there is a high rate of bladder dysfunc-
tion, reflux and hydronephrosis.3,4 Patients with high filling
or voiding pressures, decreased bladder compliance and high
Table. Comparison of the frequencies of the outcomes of interest between early (Group 1) and late (Group 2) treatment
Group 1, n = 36 Group 2, n = 31   p*
Increased BUN or serum creatinine, n (%) 12 (33.3) 19 (61.3) 0.022
Hydronephrosis, n (%) 10 (27.8) 18 (58.1) 0.012
Augmentation cystoplasty, n (%) 15 (13.9) 10 (32.3) 0.072
Recurrent upper UTI, n (%) 19 (25.0) 14 (45.2) 0.083
*Comparison of proportions between the two groups using the Chi-squared test. BUN = blood urea nitrogen; UTI = urinary tract infection.
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leak point pressure (> 40 cmH2O) have a high risk of upper-
tract damage.5 Anticholinergic drugs in combination with
CIC can preserve upper-tract function in the high-risk group.6
Joseph et al reported the effectiveness of CIC, with upper-tract
stability in 89% of patients up to the mean follow-up time of
28.4 months.7 Edelstein et al compared a group of patients
receiving late treatment who had upper-tract dilatation before
treatment with an early treatment group, and reported that
80% of patients in the late treatment group had progressive
renal deterioration while only 15% of patients in the early
treatment group had renal deterioration.8 Wu et al compared
patients with no upper-tract dilatation treated since the
neonatal period (first year of life) with similar patients treated
during childhood (after 4 years).9 They concluded that earlier
treatment showed better results in terms of rate of infection,
preservation of renal function and occurrence of hydro-
nephrosis, although the follow-up period was only 83 months.
We compared early treatment (first year of life) with late
treatment (> 3 years) over long-term follow-up (≥ 11 years).
The early treatment group showed better results in terms of
time to increased BUN and serum creatinine, degree of renal
deterioration, time to hydronephrosis, degree of upper-tract
dilatation, and time to augmentation cystoplasty. Although
comparison of the Kaplan-Meier curves between the two
groups showed only marginal significance (due to the small
sample size), the trend is quite clear. Our data thus continue to
support early treatment of neurogenic bladder in paediatric
patients born with myelomeningocele, since there is a higher
likelihood of preservation of renal function.
Early intervention for neurogenic bladder, both diagnostic
and therapeutic, and the introduction of CIC are likely to lead
to the most successful outcome.
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Figure 1. Probability curve for non-increased blood urea nitrogen
(BUN) or serum creatinine in Group 1 (solid line) and Group 2
(dashed line). Log-rank test, p = 0.078.
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Figure 2. Hydronephrosis-free probability curve for Group 1 (solid
line) and Group 2 (dashed line). Log-rank test, p = 0.028.
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Figure 3. Augmentation cystoplasty-free probability curve for Group
1 (solid line) and Group 2 (dashed line). Log-rank test, p = 0.132.
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